



Publication List July 2023 – July 2024

Summary

Directly related to Lewy Body Dementia Association-supported research and activities (n=1)

Directly related to research in dementia with Lewy bodies/Parkinson's disease with dementia (Lewy body dementia) and/or Lewy body disease (n=64)

Related to clinical research other LBD-related neurodegenerative disorders (e.g., Parkinson's disease, REM sleep behavior disorder, dementia, etc.) (n=112)

Total: 177

Manuscripts directly related to LBDA-supported research and activities

1. Bayram E, Holden SK, Fullard M, Armstrong MJ. Lewy Body Dementia Association Community Engagement Working Group. Race and Ethnicity in Lewy Body Dementia: A Narrative Review. *J Alzheimers Dis.* 2023;94(3):861-878. doi: 10.3233/JAD-230207. PMID: 37355902; PMCID: PMC10448838

Manuscripts focused on DLB/PDD

1. Jain L, Khrestian M, Formica S, Tuason ED, Pillai JA, Rao S, Oguh O, Lippa CF, Lopez OL, Berman SB, Tsuang DW, Zabetian CP, Irwin DJ, Galasko DR, Litvan I, Marder KS, Honig LS, Fleisher JE, Galvin JE, Bozoki AC, Taylor AS, Sabbagh MN, Leverenz JB, Bekris LM. ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium. *Alzheimers Dement.* 2024 Jan;20(1):549-562; PMCID: PMC10840643
2. Coughlin DG, MacLeod KR, Middleton JS, Bozoki AC, Galvin JE, Irwin DJ, Lippa CF, Litvan I, Lopez OL, Berman S, Tsuang DW, Zabetian CP, Honig LS, Marder KS, Fleisher JE, Sabbagh M, Wint D, Taylor AS, Bekris L, Leverenz JB, Galasko D. Association of CSF α -Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With

Lewy Bodies. *Neurology*. 2024 Aug 13;103(3):e209656. doi: 10.1212/WNL.0000000000209656. Epub 2024 Jul 16. PMID: 39013126; PMCID: PMC11238940

3. Maldonado-Díaz C, Hiya S, Yokoda RT, Farrell K, Marx GA, Kauffman J, Daoud EV, Gonzales MM, Parker AS, Canbeldek L, Kulumani Mahadevan LS, Crary JF, White CL 3rd, Walker JM, Richardson TE. Disentangling and quantifying the relative cognitive impact of concurrent mixed neurodegenerative pathologies. *Acta Neuropathol*. 2024 Mar 23;147(1):58. doi: 10.1007/s00401-024-02716-y. PMID: 38520489; PMCID: PMC10960766
4. Chiu SY, Chen R, Wang WE, Armstrong MJ, Boeve BF, Savica R, Ramanan V, Fields JA, Graff-Radford N, Ferman TJ, Kantarci K, Vaillancourt DE; Alzheimer's Disease Neuroimaging Initiative. Longitudinal Free-Water Changes in Dementia with Lewy Bodies. *Mov Disord*. 2024 May;39(5):836-846. doi: 10.1002/mds.29763. Epub 2024 Mar 13. PMID: 38477399; PMCID: PMC11102324
5. Wyman-Chick KA, Choudhury P, Bayram E, Abdelnour C, Matar E, Chiu SY, Ferreira D, Hamilton CA, Donaghy PC, Rodriguez-Porcel F, Toledo JB, Habich A, Barrett MJ, Patel B, Jaramillo-Jimenez A, Scott GD, Kane JPM. Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians. *Neurol Ther*. 2024 Jun;13(3):885-906. doi: 10.1007/s40120-024-00620-x. Epub 2024 May 8. PMID: 38720013; PMCID: PMC11136939
6. Mastenbroek SE, Vogel JW, Collij LE, Serrano GE, Tremblay C, Young AL, Arce RA, Shill HA, Driver-Dunckley ED, Mehta SH, Belden CM, Atri A, Choudhury P, Barkhof F, Adler CH, Ossenkoppele R, Beach TG, Hansson O. Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α -synuclein pathology. *Nat Commun*. 2024 Jun 15;15(1):5133. doi: 10.1038/s41467-024-49402-x. PMID: 38879548; PMCID: PMC11180185
7. O'Shea, DM, Arkhipenko, A, Galasko, D, Goldman, JG, Sheikh, ZH, Petrides, G, Toledo, JB, & Galvin, JE. Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions. *Front Neurol*, 2024; 15, 1395413. PMID: 38720013; PMCID: PMC11073567
8. Armstrong MJ, Dai Y, Sovich K, LaBarre B, Paulson HL, Maixner SM, Fields JA, Lunde AM, Forsberg LK, Boeve BF, Manning CA, Galvin JE, Taylor AS, Li Z. Caregiver Experiences and Burden in Moderate-Advanced Dementia With Lewy Bodies. *Neurol Clin Pract*. 2024 Jun;14(3):e200292. doi: 10.1212/CPJ.0000000000200292. Epub 2024 Apr 10. PMID: 38617555; PMCID: PMC11014644
9. Armstrong MJ, LaBarre B, Sovich K, Maixner SM, Paulson HL, Manning C, Fields JA, Lunde A, Forsberg L, Boeve BF, Galvin JE, Taylor AS, Li Z. Patient- and proxy-reported quality of life in advanced dementia with Lewy bodies. *Alzheimers Dement*. 2024 Apr;20(4):2719-2730. doi: 10.1002/alz.13745. Epub 2024 Feb 23. PMID: 38400528; PMCID: PMC11032544
10. Schumacher J, Kanel P, Dyrba M, Storch A, Bohnen NI, Teipel S, Grothe MJ. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease. *Brain*.

2023 Dec 1;146(12):4964-4973. doi: 10.1093/brain/awad226. PMID: 37403733; PMCID: PMC10689921

11. Okkels N, Grothe MJ, Taylor JP, Hasselbalch SG, Fedorova TD, Knudsen K, van der Zee S, van Laar T, Bohnen NI, Borghammer P, Horsager J. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes. *Brain*. 2024 Jul 5;147(7):2308-2324. doi: 10.1093/brain/awae069. PMID: 38437860
12. Choudhury P, Zhang Z, Adler CH, Chen K, Belden C, Driver-Dunckley E, Mehta SH, Shprecher DR, Serrano G, Shill HA, Beach TG, and AtriA. Longitudinal motor decline in Dementia with Lewy Bodies, Parkinson Disease Dementia, and Alzheimer's dementia in a community autopsy cohort. *Alzheimer's Dement* 2023; 1-11. DOI: 10.1002/alz.13357. PMID: 37422286
13. Aslam S, Manfredsson FD, Stokes A, Shill H. Advanced Parkinson's disease: A review. *Parkinsonism Related Disorders*. Available online 2/23/2024. <https://doi.org/10.1016/j.parkreldis.2024.106065>. PMID: 38418318
14. Adler CH, Halverson M, Zhang N, Shill HA, Driver-Dunckley E, Mehta SH, AtriA, Caviness JN, Serrano GE, Shprecher DR, Belden CM, Sabbagh MN, Long K, Beach TG. Conjugal synucleinopathies: A clinicopathologic study. *Mov Disord*. 2024 Apr 10. doi: 10.1002/mds.29783. Online ahead of print. PMID: 38597193
15. Coughlin DG, et al, Leverenz JB, Galasko D. Association of CSF alpha-synuclein seeding amplification assay results with clinical features of possible and probable dementia with Lewy bodies. *Neurology* 103:e209656, 2024. PMCID:PMC11238940
16. Goldman JG, et al, Leverenz JB, Taylor JP. Concerns with the new biological research criteria for synucleinopathy. *Lancet Neurol*, 23:660-661, 2024. PMID:38876736.
17. Pillai JA, Bena J, Tousi B, Rothenberg K, Keene CD, Leverenz JB. Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's pathology. *Alzheimers Dement*. 20:2564-2574, 2024. PMID: 38353367
18. Toledo JB et al, Leverenz JB, et al. ISTAART Lewy body dementias Trial Methods Working Group. Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design. *Alzheimers Dement*, 19(1): 318-332, 2023. PMCID:PMC9881193
19. Pillai JA, Bena J, Maly EF, Leverenz JB. Initial non-amnestic symptoms relate to faster rate of functional and cognitive decline compared to amnestic symptoms in neuropathologically confirmed dementias. *Alzheimers Dement*, 19:2956-2965, 2023. PMCID:PMC10350479.
20. Agarwal K, et al, Leverenz JB, et al. Lewy body dementia: Overcoming barriers and identifying solutions. *Alzheimers Dement*, 20:2298-2308, 2024. PMCID:PMC10942666.
21. Scholz SW, et al, International Lewy Body Dementia Genetics Consortium, et al. Association of cardiovascular disease management drugs with Lewy body dementia: a case-control study. *Brain Commun*, 6:fcad346, 2023. PMCID:PMC10754316

22. Levin J, Baiardi S, Quadalti C, Rossi M, Mammana A, Voglein J, et al. alpha-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden. *Alzheimers Dement.* 2024;20(6):4351-65
23. Wang HP, Scalco R, Saito N, Beckett L, Nguyen ML, Huie EZ, et al. The neuropathological landscape of small vessel disease and Lewy pathology in a cohort of Hispanic and non-Hispanic White decedents with Alzheimer disease. *Acta Neuropathol Commun.* 2024;12(1):81
24. Boeve BE, Davis AA, Ju Y, Kantarci K, Singer W, Videnovic A; NAPS co-investigators. Concerns with the new biological research criteria for synucleinopathy. *Lancet Neurology* 2024 Jul; 23(7):659-660. PMID: 38876735 DOI: 10.1016/S1474-4422(24)00213-8
25. Young, C. B., Cholerton, B., Smith, A. M., Shahid-Besanti, M., Abdelnour, C., Mormino, E. C., Hu, S. C., Chung, K. A., Peterson, A., Rosenthal, L., Pantelyat, A., Dawson, T. M., Quinn, J., Zabetian, C. P., Montine, T. J., & Poston, K. L. (2024). The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials. *Neurology*, 103(2), e209609. <https://doi.org/10.1212/WNL.0000000000209609>
26. Reho P, Saez-Atienzar S, Ruffo P, Solaiman S, Shah Z, Chia R, Kaivola K, Traynor BJ, Tilley BS, Gentleman SM, Hodges AK, Aarsland D, Monuki ES, Newell KL, Woltjer R, Albert MS, Dawson TM, Rosenthal LS, Troncoso JC, Pletnikova O, Serrano GE, Beach TG, Easwaran HP, Scholz SW. Differential methylation analysis in neuropathologically confirmed dementia with Lewy bodies. *Commun Biol.* 2024 Jan 5;7(1):35. doi: 10.1038/s42003-023-05725-x. PMID: 38182665; PMCID: PMC10770032
27. Mak E, Reid RI, Przybelski SA, Lesnick TG, Schwarz CG, Senjem ML, Raghavan S, Vemuri P, Jack CR Jr, Min HK, Jain MK, Miyagawa T, Forsberg LK, Fields JA, Savica R, Graff-Radford J, Jones DT, Botha H, St Louis EK, Knopman DS, Ramanan VK, Dickson DW, Graff-Radford NR, Ferman TJ, Petersen RC, Lowe VJ, Boeve BF, O'Brien JT, Kantarci K. Influences of amyloid- β and tau on white matter neurite alterations in dementia with Lewy bodies. *NPJ Parkinsons Dis.* 2024 Apr 3;10(1):76. doi: 10.1038/s41531-024-00684-4. PMID: 38570511
28. Walton RL, Koga S, Beasley AI, White LJ, Griesacker T, Murray ME, Kasanuki K, Hou X, Fiesel FC, Springer W, Uitti RJ, Fields JA, Botha H, Ramanan VK, Kantarci K, Lowe VJ, Jack CR, Ertekin-Taner N, Savica R, Graff-Radford J, Petersen RC, Parisi JE, Reichard RR, Graff-Radford NR, Ferman TJ, Boeve BF, Wszolek ZK, Dickson DW, Ross OA, Heckman MG. Role of GBA variants in Lewy body disease neuropathology. *Acta Neuropathol.* 2024 Mar 12;147(1):54. doi: 10.1007/s00401-024-02699-w. PMID: 38472443
29. Diaz-Galvan P, Przybelski SA, Algeciras-Schimmich A, Figdore DJ, Lesnick TG, Schwarz CG, Senjem ML, Gunter JL, Jack CR Jr, Min PH, Jain MK, Miyagawa T, Forsberg LK, Fields JA, Savica R, Graff-Radford J, Ramanan VK, Jones DT, Botha H, St Louis EK, Knopman DS, Graff-Radford NR, Ferman TJ, Petersen RC, Lowe VJ, Boeve BF, Kantarci K. Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies. *Alzheimers Dement.* 2024 Apr;20(4):2485-2496. doi: 10.1002/alz.13653. Epub 2024 Feb 8. PMID: 38329197

30. Diaz-Galvan P, Przybelski SA, Lesnick TG, Schwarz CG, Senjem ML, Gunter JL, Jack CR, Min HP, Jain M, Miyagawa T, Forsberg LK, Fields JA, Savica R, Graff-Radford J, Jones DT, Botha H, St Louis EK, Knopman DS, Ramanan VK, Ross O, Graff-Radford N, Day GS, Dickson DW, Ferman TJ, Petersen RC, Lowe VJ, Boeve BF, Kantarci K. β -Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies. *Neurology*. 2023 Jul 11;101(2):e178-e188. doi: 10.1212/WNL.0000000000207393. Epub 2023 May 18. PMID: 37202168
31. Singh NA, Goodrich AW, Graff-Radford J, Machulda MM, Sintini I, Carlos AF, Robinson CG, Reid RI, Lowe VJ, Jack CR Jr, Petersen RC, Boeve BF, Josephs KA, Kantarci K, Whitwell JL. Altered structural and functional connectivity in Posterior Cortical Atrophy and Dementia with Lewy bodies. *Neuroimage*. 2024 Apr 15; 290:120564 Epub 2024 Mar 03 PMID: 38442778 PMCID: 11019668 DOI: 10.1016/j.neuroimage.2024.120564
32. Habich A, Oltra J, Schwarz CG, Przybelski SA, Oppedal K, Inguanzo A, Blanc F, Lemstra AW, Hort J, Westman E, Segura B, Junque C, Lowe VJ, Boeve BF, Aarsland D, Dierks T, Kantarci K, Ferreira D. Grey matter networks in women and men with dementia with Lewy bodies. *NPJ Parkinsons Dis*. 2024 Apr 13; 10 (1):84 PMID: 38615089 PMCID: 11016082 DOI: 10.1038/s41531-024-00702-5
33. Oltra J, Habich A, Schwarz CG, Nedelska Z, Przybelski SA, Inguanzo A, Diaz-Galvan P, Lowe VJ, Oppedal K, Gonzalez MC, Philippi N, Blanc F, Barkhof F, Lemstra AW, Hort J, Padovani A, Rektorova I, Bonanni L, Massa F, Kramberger MG, Taylor JP, Snaedal JG, Walker Z, Antonini A, Dierks T, Segura B, Junque C, Westman E, Boeve BF, Aarsland D, Kantarci K, Ferreira D. Sex differences in brain atrophy in dementia with Lewy bodies. *Alzheimers Dement*. 2024 Mar; 20 (3):1815-1826 Epub 2023 Dec 22 PMID: 38131463 PMCID: 10947875 DOI: 10.1002/alz.13571
34. Agarwal K, Backler W, Bayram E, Bloom L, Boeve BF, Cha JH, Denslow M, Ferman TJ, Galasko D, Galvin JE, Gomperts SN, Irizarry MC, Kantarci K, Kaushik H, Kietlinski M, Koenig A, Leverenz JB, McKeith I, McLean PJ, Montine TJ, Moose SO, O'Brien JT, Panier V, Ramanathan S, Ringel MS, Scholz SW, Small J, Sperling RA, Taylor A, Taylor JP, Ward RA, Witten L, Hyman BT. Lewy body dementia: Overcoming barriers and identifying solutions. *Alzheimers Dement*. 2024 Mar; 20 (3):2298-2308 Epub 2024 Jan 24 PMID: 38265159 PMCID: 10942666 DOI: 10.1002/alz.1367
35. Miyagawa T, Vernon C, Przybelski SA, Min HK, Fields JA, Kantarci K, Lowe V, Boeve BF. Marked Decreased Tracer Binding in 123I-FP-CIT SPECT Scans From Lisdexafetamine Dismesylate Interaction: A Case Report. *Clin Neuropharmacol*. 2024 Jan 2 Epub 2024 Jan 02 PMID: 38193851 DOI: 10.1097/WNF.0000000000000579
36. Townsend LTJ, Anderson KN, Boeve BF, McKeith I, Taylor JP. Sleep disorders in Lewy body dementia: Mechanisms, clinical relevance, and unanswered questions. *Alzheimers Dement*. 2023 Jul 1. doi: 10.1002/alz.13350. Epub ahead of print. PMID: 37392199
37. Wu LY, Real R, Martinez-Carrasco A, Chia R, Lawton MA, Shoai M, Bresner C, Blauwendraat C, Singleton AB, Ryten M; International Lewy Body Dementia Genomics Consortium (Boeve – member); Scholz SW, Traynor BJ, Williams NM, Hu MTM, Ben-Shlomo Y, Grosset DG, Hardy J, Morris HR. Investigation of the genetic aetiology of Lewy body diseases with and without

dementia. *Brain Commun.* 2024 May 31;6(4):fcae190. doi: 10.1093/braincomms/fcae190. PMID: 38978726; PMCID: PMC11228432

38. Camerucci E, Mullan AF, Turcano P, Stang CD, Bower J, Benarroch EE, Boeve BF, Savica R. A Population-Based Approach to the Argument on Brain-First and Body- First Pathogenesis of Lewy Body Disease. *Ann Neurol.* 2024 Jun 11. doi: 10.1002/ana.27006. Epub ahead of print. PMID: 38860478
39. Yu E, Krohn L, Ruskey JA, Asayesh F, Spiegelman D, Shah Z, Chia R, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Bernardini A, Högl B, Stefani A, Ibrahim A, Heidbreder A, Sonka K, Dusek P, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Döring F, Cochen De Cock V, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Rouleau GA, Postuma RB; International LBD Genomics Consortium; Scholz SW, Gan-Or Z. HLA in isolated REM sleep behavior disorder and Lewy body dementia. *Ann Clin Transl Neurol.* 2023 Sep;10(9):1682-1687. doi: 10.1002/acn3.51841. Epub 2023 Jul 4. PMID: 37401389; PMCID: PMC10502660
40. Ye R, Goodheart AE, Locascio JJ, Peterec E, Properzi M, Thibault EG, Chuba E, Johnson KA, Brickhouse MJ, Touroutoglou A, Growdon JH, Dickerson BC, Gomperts SN. Differential Vulnerability of Hippocampal Subfields to Amyloid and Tau Deposition in the Lewy Body Diseases. *Neurology.* 2024 Jun 25;102(12):e209460
41. Alam JJ, Maruff P, Doctrow SR, Chu HM, Conway J, Gomperts SN, Teunissen C. Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies. *Neurology.* 2023 Oct 24;101(17):e1708-e1717
42. Liu G, Ni C, Zhan J, Li W, Luo J, Liao Z, Locascio JJ, Xian W, Chen L, Pei Z, Corvol JC, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Hung AY, Schwarzschild MA, Hayes MT, Wills AM, Ravina B, Shoulson I, Taba P, Köks S, Beach TG, Cormier-Dequaire F, Alves G, Tysnes OB, Perlmutter JS, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Scherzer CR. Mitochondrial haplogroups and cognitive progression in Parkinson's disease. *International Genetics of Parkinson Disease Progression (IGPP) Consortium. Brain.* 2023 Jan 5;146(1):42-49
43. Goodheart AE, Blackstone C. Getting to the heart of Lewy body disease. *J Clin Invest.* 2024 Jan 2;134(1):e175798
44. Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok-A-Hin YS, Lleó A, Alcolea D, van Nee M, Engelborghs S, van Alphen JL, Arezoumandan S, Chen-Plotkin A, Irwin DJ, van der Flier WM, Lemstra AW, Teunissen CE. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease. *Nat Commun.* 2023 Sep 13;14(1):5635. doi: 10.1038/s41467-023-41122-y. PMID: 37704597; PMCID: PMC10499811
45. Cousins KAQ, Irwin DJ, Chen-Plotkin A, Shaw LM, Arezoumandan S, Lee EB, Wolk DA, Weintraub D, Spindler M, Deik A, Grossman M, Tropea TF. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease. *Ann Clin Transl Neurol.* 2023

May;10(5):802-813. doi: 10.1002/acn3.51768. Epub 2023 Mar31. PMID: 37000892; PMCID: PMC10187730

46. Holden SK, Bedenfield N, Taylor AS, Bayram E, Schwilk C, Fleisher J, Duda J, Shill H, Paulson HL, Stacy K, Wood J, Corsentino P, Sha SJ, Litvan I, Irwin DJ, Quinn JF, Goldman JG, Amodeo K, Taylor JP, Boeve BF, Armstrong MJ. Research Priorities of Individuals and Caregivers With Lewy Body Dementia: A Web-based Survey. *Alzheimer Dis Assoc Disord*. 2023 Jan-Mar 01;37(1):50-58. doi:10.1097/WAD.0000000000000545. Epub 2023 Feb 23. PMID: 36821177; PMCID: PMC9971616
47. Arezoumandan S, Cousins KAQ, Ohm DT, Lowe M, Chen M, Gee J, Phillips JS, McMillan CT, Luk KC, Deik A, Spindler MA, Tropea TF, Weintraub D, Wolk DA, Grossman M, Lee V, Chen-Plotkin AS, Lee EB, Irwin DJ. Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease. *Ann Clin Transl Neurol*. 2024 Mar;11(3):673-685. doi: 10.1002/acn3.51988. Epub 2024 Jan23. PMID: 38263854; PMCID: PMC10963284
48. Fleisher JE, Suresh M, Levin ME, Hess SP, Akram F, Dodson D, Tosin M, Stebbins GT, Woo K, Ouyang B, Chodosh J. Learning to PERSEVERE: A pilot study of peer mentor support and caregiver education in Lewy body dementia. *Parkinsonism Relat Disord*. 2023 Aug;113:105492. doi: 10.1016/j.parkreldis.2023.105492. Epub 2023 Jun 24. PMID: 37385161; PMCID: PMC10527787
49. Abdelnour C, Young CB, Shahid-Besanti M, Smith A, Wilson EN, Ramos Benitez J, Vossler H, Plastini MJ, Winer JR, Kerchner GA, Cholerton B, Andreasson KI, Henderson VW, Yutsis M, Montine TJ, Tian L, Mormino EC, Poston KL. Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease. *Ann Neurol*. 2024 Jun 18
50. Xue C, Kowshik SS, Lteif D, Puducheri S, Jasodanand VH, Zhou OT, Walia AS, Guney OB, Zhang JD, Pham ST, Kaliaev A, Andreu-Arasa VC, Dwyer BC, Farris CW, Hao H, Kedar S, Mian AZ, Murman DL, O'Shea SA, Paul AB, Rohatgi S, Saint-Hilaire MH, Sartor EA, Setty BN, Small JE, Swaminathan A, Taraschenko O, Yuan J, Zhou Y, Zhu S, Karjadi C, Alvin Ang TF, Bargal SA, Plummer BA, Poston KL, Ahangaran M, Au R, Kolachalama VB. AI-based differential diagnosis of dementia etiologies on multimodal data. *Nat Med*. 2024 Jul 4
51. Plastini MJ, Abdelnour C, Young CB, Wilson EN, Shahid-Besanti M, Lamoureux J, Andreasson KI, Kerchner GA, Montine TJ, Henderson VW, Poston KL. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. *Ann Clin Transl Neurol*. 2024 Mar 4. Epub ahead of print.
52. Simuni T, Chahine LM, Poston KL, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiasi P, Foroud T, Frasier M, Gochanour C, Jennings D, Kiebertz K, Kopil CM, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner CM, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, Marek K. A biological definition of neuronal α -synuclein disease: towards an integrated staging system for research. *Lancet Neurol*. 2024 Feb;23(2):178-190.

53. Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D. Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. *Curr Opin Neurol*. 2023 Aug 1;36(4):264-275. doi: 10.1097/WCO.0000000000001173
54. Skylar-Scott IA, Sha SJ. Lewy Body Dementia: An Overview of Promising Therapeutics. *Curr Neurol Neurosci Rep*. 2023 Aug 12. doi: 10.1007/s11910-023-01292-0. Epub ahead of print. PMID: 37572228
55. Gasca-Salas C, Duff-Canning S, McArthur E, Armstrong MJ, Reginold W, Fox S, Nisenbaum R, Meaney CA, Rothberg B, Tang-Wai DF, Gill D, Eslinger PJ, Zadikoff C, Kennedy N, Marshall FJ, Mapstone M, Chou KL, Persad C, Litvan I, Mast BT, Gerstenecker AT, Weintraub S, Marras C. Predictors of cognitive change in Parkinson's disease: a two year follow-up study. *Alzheimers Dis Assoc Disord* 2023; 37(4):335-342. DOI: 10.1097/WAD.0000000000000576
56. Tholanikunnel T, Chapin BA, Armstrong MJ. Prodromal dementia with Lewy bodies: a case series of the 3 prodromal types from clinical practice. *Case Reports in Neurology* 2023; 15(1):199-206. <https://doi.org/10.1159/000533378>
57. Armstrong MJ, Barnes LL. Under-Diagnosis of Dementia with Lewy Bodies in Individuals Racialized as Black: Hypotheses Regarding Potential Contributors. *J Alzheimers Dis*. 2024;97(4):1571-1580. doi: 10.3233/JAD-231177. PMID: 38277299; PMCID: PMC10894581
58. Prins ND, de Haan W, Gardner A, Blackburn K, Chu HM, Galvin JE, Alam JJ. Phase 2A learnings incorporated into RewinD-LB, a Phase 2B clinical trial of Neflamapimod in dementia with Lewy bodies. *J Prev Alzheimers Dis* 11:549-557, 2024. (PMCID: 11061005)
59. Tolea MI, Ezzeddine R, Camacho S, Galvin JE. Emerging drugs for dementia with Lewy bodies: A review of Phase II & III trials. *Expert Opin Emerg Drugs* 8;1-14, 2023
60. Rothenberg KG, McRae SG, Dominguez-Colman LM, Shutes-David A, Tsuang DW. Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series. *Am J Case Rep*. 2023 Sep 30;24:e939806. doi: 10.12659/AJCR.939806. PMID: 37775968
61. Holden SK. Updates in fluid, tissue, and imaging biomarkers for dementia with Lewy bodies and implications for biologically based disease definitions. *Current Treatment Options in Neurology*. 2024; 26, 189–201
62. Holden SK, Trottier Z, Farley M (2024). Lewy Body Dementia. In Filley C (Ed.), *Encyclopedia of the Neurological Sciences*, 3rd Edition. Oxford, UK: Elsevier
63. Carlisle TC, Medina LD, Holden SK. Initial development of a pragmatic tool to estimate cognitive decline risk focusing on potentially modifiable factors in Parkinson's disease. *Front Neurosci*. 2023 Oct 24;17:1278817
64. Gibbons CH, Levine T, Adler C, Bellaire B, Wang N, Stohl J, Agarwal P, Aldridge GM, Barboi A, Evidente VGH, Galasko D, Geschwind MD, Gonzalez-Duarte A, Gil R, Gudesblatt M, Isaacson SH, Kaufmann H, Khemani P, Kumar R, Lamotte G, Liu AJ, McFarland NR, Miglis M, Reynolds

A, Sahagian GA, Saint-Hillaire MH, Schwartzbard JB, Singer W, Soileau MJ, Vernino S, Yerstein O, Freeman R. Skin Biopsy Detection of Phosphorylated α -Synuclein in Patients With Synucleinopathies. *JAMA*. 2024 Apr 16;331(15):1298-1306. doi: 10.1001/jama.2024.0792. PMID: 38506839; PMCID: PMC10955354

Manuscripts which are LBD-related, e.g. PD and RBD

1. Mantri S, Purks JL, Kinel D, Arbatti L, Hosamath A, Allen A, Amara A, Anderson K, Chahine LM, Eberly S, Mathur S, Standaert D, Oakes D, Weintraub D, Shoulson I, Marras C. In Their Own Words: Fears Expressed by People with Parkinson's Disease in an Online Symptom Database. *J Parkinsons Dis*. 2024;14(4):865-872. doi: 10.3233/JPD-230305. PMID: 38669556; PMCID: PMC11191490
2. Weintraub D, Marras C, Amara A, Anderson KE, Chahine LM, Eberly S, Hosamath A, Kinel D, Mantri S, Mathur S, Oakes D, Purks JL, Standaert DG, Shoulson I, Arbatti L. Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease. *Mov Disord*. 2024 Apr;39(4):706-714. doi: 10.1002/mds.29725. Epub 2024 Feb 6. PMID: 38318953
3. Griffith G, Lamotte G, Mehta N, Fan P, Nikolich J, Springman V, Suttman E, Joslin E, Balfany K, Dunlap M, Kohrt WM, Christiansen CL, Melanson EL, Josbeno D, Chahine LM, Patterson CG, Corcos DM. Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson's Disease. *J Parkinsons Dis*. 2024;14(1):121-133. doi: 10.3233/JPD-230006. PMID: 38189712; PMCID: PMC10836543
4. Young VM, Bernal R, Pollet E, Serrano-Rubio L, Gaona C, Himali JJ, Seshadri S, González DA, Gonzales MM. Deep Sleep, Olfactory Loss, and Cognition in Early-stage Parkinson's Disease: Pilot Study Results. *Gerontol Geriatr Med*. 2024 Jun 24;10:23337214241262925. doi: 10.1177/23337214241262925. PMID: 39045212; PMCID: PMC11265233
5. González DA, Wang D, Pollet E, Velarde A, Horn S, Coss P, Vaou O, Wang J, Li C, Seshadri S, Miao H, Gonzales MM. Performance of the Dreem 2 EEG headband, relative to polysomnography, for assessing sleep in Parkinson's disease. *Sleep Health*. 2024 Feb;10(1):24-30. doi: 10.1016/j.sleh.2023.11.012. Epub 2023 Dec 27. PMID: 38151377
6. Alcalá-Zúniga D, Espinoza-Torres E, Das RK, Vargas M, Maldonado O, Benavides O, Manojkumar A, de la Garza R, Davila N, Perez I, Martinez AH, Roy D, López-Juárez A, Zarei MM, Baker KA, Gil M, Rodrigo H, de Erausquin GA, Roy U. Enriched Environment Contributes to the Recovery from Neurotoxin-Induced Parkinson's Disease Pathology. *Mol Neurobiol*. 2024 Feb 13. doi: 10.1007/s12035-024-03951-w. Epub ahead of print. PMID: 38349515
7. Xia R, Jian X, Rodrigue AL, Bressler J, Boerwinkle E, Cui B, Daviglius ML, DeCarli C, Gallo LC, Glahn DC, Knowles EEM, Moon JY, Mosley TH, Satizabal CL, Sofer T, Tarraf W, Testai F, Blangero J, Seshadri S, González HM, Fornage M. Admixture mapping of cognitive function in

diverse Hispanic and Latino adults: Results from the Hispanic Community Health Study/Study of Latinos. *Alzheimers Dement.* 2024 Jul 1. doi: 10.1002/alz.14082. Epub ahead of print. PMID: 38946675

8. Mukadam N, Wolters FJ, Walsh S, Wallace L, Brayne C, Matthews FE, Sacuiu S, Skoog I, Seshadri S, Beiser A, Ghosh S, Livingston G. Changes in prevalence and incidence of dementia and risk factors for dementia: an analysis from cohort studies. *Lancet Public Health.* 2024 Jul;9(7):e443-e460. doi: 10.1016/S2468-2667(24)00120-8. PMID: 38942556
9. Aguirre A, Hilsabeck R, Smith T, Xie B, He D, Wang Z, Zou N. Assessing the Quality of ChatGPT Responses to Dementia Caregivers' Questions: Qualitative Analysis. *JMIR Aging.* 2024 May 6;7:e53019. doi: 10.2196/53019. PMID: 38722219; PMCID: PMC11089887
10. Chia R, Ray A, Shah Z, Ding J, Ruffo P, Fujita M, Menon V, Saez-Atienzar S, Reho P, Kaivola K, Walton RL, Reynolds RH, Karra R, Sait S, Akcimen F, Diez-Fairen M, Alvarez I, Fanciulli A, Stefanova N, Seppi K, Duerr S, Leys F, Krismer F, Sidoroff V, Zimprich A, Pirker W, Rascol O, Foubert-Samier A, Meissner WG, Tison F, Pavy-Le Traon A, Pellecchia MT, Barone P, Russillo MC, Marín-Lahoz J, Kulisevsky J, Torres S, Mir P, Perrián MT, Proukakis C, Chelban V, Wu L, Goh YY, Parkkinen L, Hu MT, Kobylecki C, Saxon JA, Rollinson S, Garland E, Biaggioni I, Litvan I, Rubio I, Alcalay RN, Kwei KT, Lubbe SJ, Mao Q, Flanagan ME, Castellani RJ, Khurana V, Ndayisaba A, Calvo A, Mora G, Canosa A, Floris G, Bohannan RC, Moore A, Norcliffe-Kaufmann L, Palma JA, Kaufmann H, Kim C, Iba M, Masliah E, Dawson TM, Rosenthal LS, Pantelyat A, Albert MS, Pletnikova O, Troncoso JC, Infante J, Lage C, Sánchez-Juan P, Serrano GE, Beach TG, Pastor P, Morris HR, Albani D, Clarimon J, Wenning GK, Hardy JA, Ryten M, Topol E, Torkamani A, Chiò A, Bennett DA, De Jager PL, Low PA, Singer W, Cheshire WP, Wszolek ZK, Dickson DW, Traynor BJ, Gibbs JR, Dalgard CL, Ross OA, Houlden H, Scholz SW. Genome sequence analyses identify novel risk loci for multiple system atrophy. *Neuron.* 2024 Jul 3;112(13):2142-2156.e5. doi: 10.1016/j.neuron.2024.04.002. Epub 2024 May 2. PMID: 38701790; PMCID: PMC11223971
11. Kalaria R, Maestre G, Mahinrad S, Acosta DM, Akinyemi RO, Alladi S, Allegri RF, Arshad F, Babalola DO, Baiyewu O, Bak TH, Bellaj T, Brodie-Mends DK, Carrillo MC, Celestin KK, Damasceno A, de Silva RK, de Silva R, Djibuti M, Dreyer AJ, Ellajosyula R, Farombi TH, Friedland RP, Garza N, Gbessemehlan A, Georgiou EE, Govia I, Grinberg LT, Guerchet M, Gugssa SA, Gumikiriza-Onoria JL, Hogervorst E, Hornberger M, Ibanez A, Ihara M, Issac TG, Jönsson L, Karanja WM, Lee JH, Leroi I, Livingston G, Manes FF, Mbakile-Mahlanza L, Miller BL, Musyimi CW, Mutiso VN, Nakasujja N, Ndetei DM, Nightingale S, Novotni G, Nyamayaro P, Nyame S, Ogeng'o JA, Ogunniyi A, de Oliveira MO, Okubadejo NU, Orrell M, Paddick SM, Pericak-Vance MA, Pirtosek Z, Potocnik FCV, Raman R, Rizig M, Rosselli M, Salokhiddinov M, Satizabal CL, Sepulveda-Falla D, Seshadri S, Sexton CE, Skoog I, George-Hyslop PHS, Suemoto CK, Thapa P, Udeh-Momoh CT, Valcour V, Vance JM, Varghese M, Vera JH, Walker RW, Zetterberg H, Zewde YZ, Ismail O. The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact. *Alzheimers Dement.* 2024 Jun;20(6):4290-4314. doi: 10.1002/alz.13836. Epub 2024 May 2. PMID: 38696263; PMCID: PMC11180946
12. Danner B, Gonzalez AD, Corbett WC, Alhneif M, Etemadmoghadam S, Parker-Garza J, Flanagan ME. Brain banking in the United States and Europe: Importance, challenges, and

future trends. *J Neuropathol Exp Neurol.* 2024 Mar 20;83(4):219-229. doi: 10.1093/jnen/nlae014. PMID: 38506125; PMCID: PMC10951968

13. Choudhury P, Lee-Iannotti JK, Busicescu AO, Rangan P, Fantini ML, Avidan AY, Bliwise DL, Criswell SR, During EH, Elliott JE, Fields JA, Gagnon JF, Howell MJ, Huddleston DE, McLeland J, Mignot E, Miglis MG, Lim MM, Pelletier A, Schenck CH, Shprecher D, St Louis EK, Videnovic A, Ju YS, Boeve BF, Postuma R; as the NAPS Consortium. Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium. *Neurology.* 2024 Feb 13;102(3):e208008. doi: 10.1212/WNL.000000000208008. Epub 2024 Jan 5. Erratum in: *Neurology.* 2024 May;102(10):e209355. doi: 10.1212/WNL.000000000209355. PMID: 38181331; PMCID: PMC11097765
14. Tremblay C, Aslam S, Walker JE, Lorenzini I, Intorcchia AJ, Arce RA, Choudhury P, Adler CH, Shill HA, Driver-Dunckley E, Mehta S, Piras IS, Belden CM, Atri A, Beach TG, Serrano GE. RNA sequencing of olfactory bulb in Parkinson's disease reveals gene alterations associated with olfactory dysfunction. *Neurobiol Dis.* 2024 Jun 15;196:106514. doi: 10.1016/j.nbd.2024.106514. Epub 2024 Apr 24. PMID: 38663633; PMCID: PMC11132317
15. Lench DH, Turner TH, Wetmore E, Rodriguez-Porcel FJ, Revuelta GJ. Integrity of the nucleus basalis of Meynert and self-reported cognitive dysfunction during wearing-off periods in Parkinson's disease. *Brain Imaging Behav.* 2024 Feb;18(1):256-261. doi: 10.1007/s11682-023-00817-y. Epub 2023 Oct 27. PMID: 37889445
16. Kegelmeyer DA, Minarsch R, Kostyk SK, Kline D, Smith R, Kloos AD. Use of a Robotic Walking Device for Home and Community Mobility in Parkinson Disease: A Randomized Controlled Trial. *J Neurol Phys Ther.* 2024 Apr 1;48(2):102-111. doi: 10.1097/NPT.0000000000000467. Epub 2024 Mar 4. PMID: 38441461
17. Pagano, J., Fong, J.C., Wood, E.M., Paul, R.A., Goldman, J.S., Klee, V., Rumbaugh, M., Lucente, D.E., Chambers, C. (2024). Clinical Genetic Testing for Alzheimer's Disease and Related Dementias. *Practical Neurology*
18. Garwood M, Vijayakumar P, Bohnen NI, Koeppe RA, Kotagal V. Serotonin transporter density in isolated rapid eye movement sleep behavioral disorder. *Front Sleep.* 2024;2:1298854. doi: 10.3389/frsle.2023.1298854. Epub 2024 Jan 29. PMID: 38765701; PMCID: PMC11101191
19. Liao JY, Bohnen NI. Is heart rate variability the heart of the matter for freezing of gait? *Parkinsonism Relat Disord.* 2023 Aug;113:105763. doi: 10.1016/j.parkreldis.2023.105763. Epub 2023 Jul 11. PMID: 37468360
20. Slingerland S, van der Zee S, Carli G, Slomp AC, Boertien JM, d'Angremont E, Bohnen NI, Albin RL, van Laar T. Cholinergic innervation topography in GBA-associated de novo Parkinson's disease patients. *Brain.* 2024 Mar 1;147(3):900-910. doi: 10.1093/brain/awad323. PMID: 37748026; PMCID: PMC10907081
21. Roytman S, Paalanen R, Griggs A, David S, Pongmala C, Koeppe RA, Scott PJH, Marusic U, Kanel P, Bohnen NI. Cholinergic system correlates of postural control changes in Parkinson's

- disease freezers. *Brain*. 2023 Aug 1;146(8):3243-3257. doi: 10.1093/brain/awad134. PMID: 37086478; PMCID: PMC10393403
22. Crowley SJ, Kanel P, Roytman S, Bohnen NI, Hampstead BM. Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson's disease. *Brain*. 2024 May 3;147(5):1799-1808. doi: 10.1093/brain/awad420. PMID: 38109781; PMCID: PMC11068112
 23. Marras C, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, Van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Mollenhauer B, Postuma RB, Rodríguez-Violante M, Simuni T, Weintraub D, Lawton M, Mestre TA. Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach. *Mov Disord*. 2024 Mar;39(3):462-471. doi: 10.1002/mds.29708. Epub 2024 Jan 20. PMID: 38243775
 24. Hodnik T, Roytman S, Bohnen NI, Marusic U. Beta-Gamma Phase-Amplitude Coupling as a Non-Invasive Biomarker for Parkinson's Disease: Insights from Electroencephalography Studies. *Life (Basel)*. 2024 Mar 15;14(3):391. doi: 10.3390/life14030391. PMID: 38541715; PMCID: PMC10971628
 25. Su C, et al, Leverenz JB, et al. Identification of Parkinson's disease PACE subtypes and repurposing treatment through integrative analyses of multimodal data. *NPJ Digit Med*, 7:184, 2024. PMCID: PMC11233682
 26. Hurst C, Dismore L, Granic A, Tullo E, Noble JM, Hillman SJ, et al. Attitudes and barriers to resistance exercise training for older adults living with multiple long-term conditions, frailty, and a recent deterioration in health: qualitative findings from the Lifestyle in Later Life - Older People's Medicine (LiLL-OPM) study. *BMC Geriatr*. 2023;23(1):772
 27. Hurst C, Dismore L, Granic A, Tullo E, Noble JM, Hillman SJ, et al. Feasibility of engaging older adults living with multiple long-term conditions, frailty, and a recent deterioration in health in a study of lifestyle: protocol for the LiLL-OPM study. *J Frailty Sarcopenia Falls*. 2023;8(2):127-35
 28. Ryvicker M, Barron Y, Song J, Zolnoori M, Shah S, Burgdorf JG, et al. Using Natural Language Processing to Identify Home Health Care Patients at Risk for Diagnosis of Alzheimer's Disease and Related Dementias. *J Appl Gerontol*. 2024:7334648241242321
 29. Elliot JE, Keil AT, Bryant-Ekstrand, M, Ligman, BR, Lim MM, Zitser J, During EH, Postuma RB, Pelletier A, Gagnon JF, St. Louis EK, David AA, Forsberg LK, Fields JA, Huddleston DE, Bliwise DL, Avidan AY, Howell MJ, Schenck CH, Criswell SR, Videnovic A, Lee-Iannotti JK, Boeve BF, Ju Y, Miglis MG, NAPS Consortium. Frequency of orthostatic hypotension in isolated REM sleep behavior disorder: The North American Prodromal Synucleinopathy cohort. *Neurology*. *Neurology*. (2023) Dec 12;101(24):e2545-e2559. PMID: 37857496. doi: 10.1212/WNL.0000000000207883
 30. Elliott JE, Ligman BR, Bryant-Ekstrand MD, Keil AT, Powers K, Olivo C, Neilson L, Postuma RB, Pelletier A, Gagnon JF, Gan-Or Z, Yu E, Liu L, St Louis EK, Forsberg LK, Fields JA, Ross OA, Huddleston DE, Bliwise DL, Avidan AY, Howell MJ, Schenck CH, McLeland J, Criswell SR, Videnovic A, During EH, Miglis MG, Shprecher DR, Lee-Iannotti JK, Boeve BF, Ju YS, Lim MM;

North American Prodromal Synucleinopathy (NAPS) Consortium. Comorbid neurotrauma increases neurodegenerative-relevant cognitive, motor, and autonomic dysfunction in patients with REM sleep behavior disorder: A substudy of the North American Prodromal Synucleinopathy Consortium. *Sleep*. (2024) Jan 5:zsae007. PMID: 38181205. doi: 10.1093/sleep/zsae007

31. Berger SL, Seemiller J, Rosenthal LS. Synuclein Seed Amplification in the Cerebrospinal Fluid: Research and Clinical Implications. *Mov Disord*. 2023 Nov;38(11):1990-1991. doi: 10.1002/mds.29619. Epub 2023 Oct 20. PMID: 37860997
32. De Francesco S, Crema C, Archetti D, Muscio C, Reid RI, Nigri A, Bruzzone MG, Tagliavini F, Lodi R, D'Angelo E, Boeve B, Kantarci K, Firbank M, Taylor JP, Tiraboschi P, Redolfi A, RIN - Neuroimaging Network. Differential diagnosis of neurodegenerative dementias with the explainable MRI based machine learning algorithm MUQUBIA. *Sci Rep*. 2023 Oct 13; 13(1):17355 PMID: 37833302 PMCID: 10575864 DOI: 10.1038/s41598-023-43706-6
33. Arnaldi D, Mattioli P, Raffa S, Pardini M, Massa F, Iranzo A, Perissinotti A, Niñerola-Baizán A, Gaig C, Serradell M, Muñoz-Lopetegui A, Mayà G, Liguori C, Fernandes M, Placidi F, Chiaravallotti A, Šonka K, Dušek P, Zogala D, Trnka J, Boeve BF, Miyagawa T, Lowe VJ, Miyamoto T, Miyamoto M, Puligheddu M, Figorilli M, Serra A, Hu MT, Klein JC, Bes F, Kunz D, Cochen De Cock V, de Verbizier D, Plazzi G, Antelmi E, Terzaghi M, Bossert I, Kulcsárová K, Martino A, Giuliani A, Pagani M, Nobili F, Morbelli S; International REM Sleep Behavior Disorder Study Group. Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy. *Ann Neurol*. 2024 Jun;95(6):1178-1192. doi: 10.1002/ana.26902. Epub 2024 Mar 11. PMID: 38466158; PMCID: PMC11102309
34. McCarter SJ, Camerucci E, Mullan AF, Stang CD, Turcano P, St Louis EK, Boeve BF, Savica R. Sleep Disorders in Early-Onset Parkinsonism: A Population-Based Study. *J Parkinsons Dis*. 2023 Sep 20. doi: 10.3233/JPD-230045. Epub ahead of print. PMID: 37742659
35. Leclair-Visonneau L, Feemster JC, Bibi N, Gossard TR, Jagielski JT, Strainis EP, Carvalho DZ, Timm PC, Bliwise DL, Boeve BF, Silber MH, McCarter SJ, St Louis EK. Contemporary diagnostic visual and automated polysomnographic REM sleep without atonia thresholds in isolated REM sleep behavior disorder. *J Clin Sleep Med*. 2023 Oct 12. doi: 10.5664/jcsm.10862. Epub ahead of print. PMID: 37823585
36. Levendowski DJ, Neylan TC, Walsh CM, Tsuang D, Salat D, Hamilton JM, Lee-Iannotti JK, Berka C, Mazeika G, Boeve BF, St Louis EK. Proof-of-concept for characterization of neurodegenerative disorders utilizing two non-REM sleep biomarkers. *Front Neurol*. 2023 Oct 20;14:1272369. doi: 10.3389/fneur.2023.1272369. PMID: 37928153; PMCID: PMC10623683
37. Cho Y, Levendowski DJ, Walsh CM, Tsuang D, Lee-Iannotti JK, Berka C, Mazeika G, Salat D, Hamilton JM, Boeve BF, Neylan TC, St Louis EK. Autonomic dysregulation during sleep in Parkinsonian spectrum disorders - A proof of concept. *Parkinsonism Relat Disord*. 2023 Dec;117:105905. doi: 10.1016/j.parkreldis.2023.105905. Epub 2023 Nov 3. PMID: 37939637
38. Rose KN, Schwarzschild MA, Gomperts SN. Clearing the Smoke: What Protects Smokers from Parkinson's Disease? *Mov Disord*. 2024 Feb;39(2):267-272

39. Rose KN, Zorlu M, Xue X, Fassini A, Cai W, Lin S, Webb P, Schwarzschild MA, Chen X, Gomperts SN. Neuroprotection of low dose carbon monoxide in Parkinson's disease models commensurate with the reduced risk of Parkinson's among smokers. *Npj Parkinson's Disease*. 2024 Aug 22;10(1):152
40. McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2024 Jan;23(1):37-45. doi: 10.1016/S1474-4422(23)00378-2.PMID: 38101901
41. Sandau US, Wiedrick JT, McFarland TJ, Galasko DR, Fanning Z, Quinn JF, Saugstad JA. Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers. *Sci Rep*. 2024 Jan 25;14(1):2148. doi: 10.1038/s41598-024-52681-5.PMID: 38272952
42. Sandau US, Magaña SM, Costa J, Nolan JP, Ikezu T, Vella LJ, Jackson HK, Moreira LR, Palacio PL, Hill AF, Quinn JF, Van Keuren-Jensen KR, McFarland TJ, Palade J, Sribnick EA, Su H, Vekrellis K, Coyle B, Yang Y, Falcón-Perez JM, Nieuwland R, Saugstad JA; International Society for Extracellular Vesicles Cerebrospinal Fluid Task Force. Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies. *J Extracell Vesicles*. 2024 Jan;13(1):e12397. doi: 10.1002/jev2.12397.PMID: 38158550
43. Merrill NJ, Davidson WS, He Y, Díaz Ludovico I, Sarkar S, Berger MR, McDermott JE, Van Eldik LJ, Wilcock DM, Monroe ME, Kyle JE, Bruce KD, Heinecke JW, Vaisar T, Raber J, Quinn JF, Melchior JT. Human cerebrospinal fluid contains diverse lipoprotein subspecies enriched in proteins implicated in central nervous system health. *Sci Adv*. 2023 Sep;9(35):eadi5571. doi: 10.1126/sciadv.adi5571. Epub 2023 Aug 30.PMID: 37647397
44. Scott GD, Neilson LE, Woltjer R, Quinn JF, Lim MM. Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease. *Mov Disord*. 2023 Aug;38(8):1483-1492. doi: 10.1002/mds.29457. Epub 2023 Jun 13.PMID: 37309872
45. Neilson LE, Quinn JF, Lim MM. Screening and Targeting Risk Factors for Prodromal Synucleinopathy: Taking Steps toward a Prescriptive Multi-modal Framework. *Aging Dis*. 2023 Aug 1;14(4):1243-1263. doi: 10.14336/AD.2022.1024.PMID: 37307836
46. Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, Kieburtz K, Marek K, Coffey CS; Parkinson's Progression Markers Initiative. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. *J Parkinsons Dis*. 2023;13(6):899-916. doi: 10.3233/JPD-223433. PMID: 37458046; PMCID: PMC10578214
47. Weintraub D, Picillo M, Cho HR, Caspell-Garcia C, Blauwendraat C, Brown EG, Chahine LM, Coffey CS, Dobkin RD, Foroud T, Galasko D, Kieburtz K, Marek K, Merchant K, Mollenhauer B,

- Poston KL, Simuni T, Siderowf A, Singleton A, Seibyl J, Tanner CM; Parkinson's Progression Markers Initiative. Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study. *Mov Disord Clin Pract.* 2023 Apr 25;10(6):943-955. doi: 10.1002/mdc3.13751. PMID: 37332638; PMCID: PMC10272925
48. Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips J, Chen-Plotkin AS Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud TM, Toga AW, Tanner CM, Kieburtz KD, Mollenhauer B, Galasko D, Hutten S, Weintraub D, Siderowf AD, Marek K, Poston KL, Shaw LM; Parkinson's Progression Markers Initiative. Evaluation of ATN Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease. *Neurology.* 2024 Feb;102(4):e208033. doi: 10.1212/WNL.000000000208033. Epub 2024 Feb 2. PMID: 38306599
 49. Tropea TF, Hartstone W, Amari N, Baum D, Rick J, Suh E, Zhang H, Paul RA, Han N, Zack R, Brody EM, Albuja I, James J, Spindler M, Deik A, Aamodt WW, Dahodwala N, Hamedani A, Lasker A, Hurtig H, Stern M, Weintraub D, Vaswani P, Willis AW, Siderowf A, Xie SX, Van Deerlin V, Chen-Plotkin AS. Genetic and phenotypic characterization of Parkinson's disease at the clinic-wide level. *NPJ Parkinsons Dis.* 2024 May 3;10(1):97. doi: 10.1038/s41531-024-00690-6. PMID: 38702337; PMCID: PMC11068880
 50. Coughlin DG, Irwin DJ. Fluid and Biopsy Based Biomarkers in Parkinson's Disease. *Neurotherapeutics.* 2023 Jul;20(4):932-954. doi:10.1007/s13311-023-01379-z. Epub 2023 May 3. PMID: 37138160; PMCID: PMC10457253
 51. Robinson JL, Xie SX, Baer DR, Suh E, Van Deerlin VM, Loh NJ, Irwin DJ, McMillan CT, Wolk DA, Chen-Plotkin A, Weintraub D, Schuck T, Lee VMY, Trojanowski JQ, Lee EB. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. *Brain.* 2023 Jun 1;146(6):2557-2569. doi: 10.1093/brain/awad059. PMID: 36864661; PMCID: PMC10232273
 52. Cousins KAQ, Phillips JS, Das SR, O'Brien K, Tropea TF, Chen-Plotkin A, Shaw LM, Nasrallah IM, Mechanic-Hamilton D, McMillan CT, Irwin DJ, Lee EB, Wolk DA. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease. *Alzheimers Dement.* 2024 Jun;20(6):3889-3905. doi: 10.1002/alz.13777. Epub 2024 Apr 21. PMID: 38644682; PMCID: PMC11180939
 53. Dratch L, Azage M, Baldwin A, Johnson K, Paul RA, Bardakjian TM, Michon SC, Amado DA, Baer M, Deik AF, Elman LB, Gonzalez-Alegre P, Guo MH, Hamedani AG, Irwin DJ, Lasker A, Orthmann-Murphy J, Quinn C, Tropea TF, Scherer SS, Ellis CA. Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts. *J Neurol.* 2024 Feb;271(2):733-747. doi:10.1007/s00415-023-12058-6. Epub 2023 Oct 27. PMID: 37891417; PMCID: PMC11095966
 54. Labuschagne D, Fleisher JE, Woo K, Fitchett G. Feasibility and Acceptability of Implementing Dignity Therapy as a Supportive Intervention for Individuals with Advanced Neurodegenerative Disease. *J Pain Symptom Manage.* 2024 Feb 1:S0885-3924(24)00055-1. doi: 10.1016/j.jpainsymman.2024.01.034. Epub ahead of print. PMID: 38307374

55. Fleisher, J.E., Woo, K., Chodosh, J. (2024). The Interdisciplinary Home Visit Program for Individuals with Advanced Parkinson's Disease. In: Malone, M.L., Boltz, M., Macias Tejada, J., White, H. (eds) *Geriatrics Models of Care*. Springer, Cham. https://doi.org/10.1007/978-3-031-56204-4_38
56. Young CB, Cholerton B, Smith AM, Shahid-Besanti M, Abdelnour C, Mormino EC, Hu SC, Chung KA, Peterson A, Rosenthal L, Pantelyat A, Dawson TM, Quinn J, Zabetian CP, Montine TJ, Poston KL. The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials. *Neurology*. 2024 Jul 23;103(2):e209609.
57. Cai W, Young CB, Yuan R, Lee B, Ryman S, Kim J, Yang L, Levine TF, Henderson VW, Poston KL, Menon V. Subthalamic nucleus-language network connectivity predicts dopaminergic modulation of speech function in Parkinson's disease. *Proc Natl Acad Sci U S A*. 2024 May 28;121(22):e2316149121
58. Rutledge J, Lehallier B, Zarifkar P, Losada PM, Shahid-Besanti M, Western D, Gorijala P, Ryman S, Yutsis M, Deutsch GK, Mormino E, Trelle A, Wagner AD, Kerchner GA, Tian L, Cruchaga C, Henderson VW, Montine TJ, Borghammer P, Wyss-Coray T, Poston KL. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease. *Acta Neuropathol*. 2024 Mar 11;147(1):52
59. Winer JR, Lok R, Weed L, He Z, Poston KL, Mormino EC, Zeitzer JM. Impaired 24-h activity patterns are associated with an increased risk of Alzheimer's disease, Parkinson's disease, and cognitive decline. *Alzheimers Res Ther*. 2024 Feb 14;16(1):35
60. Smith V, Younes K, Poston KL, Mormino EC, Young CB. Reliability of remote National Alzheimer's Coordinating Center Uniform Data Set data. *Alzheimers Dement (Amst)*. 2023 Nov 29;15(4):e12498
61. Nerrise F, Zhao Q, Poston KL, Pohl KM, Adeli E. An Explainable Geometric-Weighted Graph Attention Network for Identifying Functional Networks Associated with Gait Impairment. *Med Image Comput Comput Assist Interv*. 2023 Oct;14221:723-733
62. Kerestes R, Laansma MA, Owens-Walton C, Perry A, van Heese EM, Al-Bachari S, Anderson TJ, Assogna F, Aventura ÍK, van Balkom TD, Berendse HW, van den Berg KRE, Betts R, Brioschi R, Carr J, Cendes F, Clark LR, Dalrymple-Alford JC, Dirx MF, Druzgal J, Durrant H, Emsley HCA, Garraux G, Haroon HA, Helmich RC, van den Heuvel OA, João RB, Johansson ME, Khachatryan SG, Lochner C, McMillan CT, Melzer TR, Mosley PE, Newman B, Opriessnig P, Parkes LM, Pellicano C, Piras F, Pitcher TL, Poston KL, Rango M, Roos A, Rummel C, Schmidt R, Schwingenschuh P, Silva LS, Smith V, Squarcina L, Stein DJ, Tavadyan Z, Tsai CC, Vecchio D, Vriend C, Wang JJ, Wiest R, Yasuda CL, Young CB, Jahanshad N, Thompson PM, van der Werf YD, Harding IH; ENIGMA-Parkinson's Study. Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study. *Mov Disord*. 2023 Dec;38(12):2269-2281
63. Wollney EN, Bylund CL, Bedenfield N, Parker ND, Rosselli M, Curiel Cid RE, Kitaigorodsky M, Armstrong MJ. Persons living with dementia and caregivers' communication preferences for

receiving a dementia diagnosis. *PEC Innov.* 2024 Jan 11;4:100253. doi: 10.1016/j.pecinn.2024.100253. PMID: 38298558; PMCID: PMC10828581

64. Kuharic M, Kulbokas V, Hanson K, Nazari JL, Shah KK, Nguyen A, Hensle T, Marras C, Armstrong MJ, Jalundhwala YJ, Pickard AS. OFF episode quality of life impact scale (OFFELIA): A new measure of quality of life for off episodes in Parkinson's disease. *Parkinsonism Relat Disord.* 2024 Jun;123:106070. doi: 10.1016/j.parkreldis.2024.106070. PMID: 38503261
65. Wollney EN, Armstrong MJ, Hampton CN, McCall-Junkin P, Bedenfield N, Fisher CL, Bylund CL. Triadic Communication in Medical Encounters Including Individuals With Dementia: A Scoping Review. *Alzheimer Dis Assoc Disord.* 2024 Apr-Jun 01;38(2):213-225. doi: 10.1097/WAD.0000000000000626. PMID: 38812448
66. Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Huang Y, Armstrong MJ, Svensson M, Virnig B, Bian J, Guo J. 750-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Incident Parkinson's Disease in U.S. Older Adults with Type 2 Diabetes. *Diabetes.* 2024 June; 73(Supplement_1):750-P. <https://doi.org/10.2337/db24-750-P>
67. Galvin JE, Chang LC, Estes P, Harris HM, Fung E. Cognitive assessment with Cognivue Clarity: Psychometric properties and normative ranges in a diverse population. *J Alzheimers Dis* 2024 Jun 14 doi:10.3233/JAD-240331 [Online ahead of print]
68. Besser LM, Edwards K, Lobban NS, Tolea MI, Galvin JE. Social Determinants of Health, Risk and Resilience against Alzheimer's Disease and Related Dementias: The Healthy Brain Initiative. *J Alzheimers Dis Rep.* 2024 Apr 8;8(1):637-646 (PMCID:11091729)
69. Nassajpour M, Shuqair M, Rosenfeld A, Tolea MI, Galvin JE, Ghoraani B. Objective estimation of m-CTSIB balance test scores using wearable sensors and machine learning. *Front Digit Health* 6:1366176, 2024 (PMCID: 11066210)
70. Seifallahi M, Galvin JE, Ghoraani B. Curve walking reveals more gait impairments in older adults with mild cognitive impairment than straight walking: A Kinect camera-based study. *J Alzheimers Dis Rep* 8:423-435, 2024 (PMCID: 10977465)
71. O'Shea DM, Camacho S, Ezzeddine R, Besser L, Tolea MI, Wang L, Galvin C, Gibbs G, Galvin JE. The mediating role of cortical atrophy on the relationship between resilience index and cognitive function: Findings from the Healthy Brain Initiative. *J Alzheimers Dis* 2024 Mar 14 doi: 10.3233/JAD-231346 [Online ahead of print]
72. Getz SJ, Levin BE, Galvin JE. The assessment of situational judgement questionnaire: A novel instrument to detect susceptibility to financial scamming. *J Alzheimers Dis* 97:1365-1379, 2024
73. Boltz M, Mogle J, Kuzmik A, BeLue R, Leslie D, Galvin JE, Renick B. Testing an intervention to improve posthospital outcomes in persons living with dementia and their family care partners. *Innov Aging*, 7:igad083, 2023 (PMCID:10573730)

74. Kuzmik A, Boltz M, Resnick B, Drazich BF, Galvin JE. Gender, Pain, and Function Associated With Physical Activity After Hospitalization in Persons Living With Dementia. *Alzheimer Dis Assoc Disord.* 37:357-362, 2023
75. Kuzmik A, BeLue R, Resnick B, Rodriguez M, Berish D, Galvin JE, Boltz M. Caregiver preparedness is associated with desire to seek long-term care admission of hospitalized persons with dementia. *Int J Geriatr Psychiatry* 38:e6006, 2023
76. Lassell RKF, Lin S-Y, Convery K, Fletcher J, Chippendale T, Jones T, Furga A, Galvin JE, Rupper RW, Brody AA. Neuropsychiatric symptoms in people living with dementia receiving home health services. *J Am Geriatr Soc.* 71:3865-3873, 2023
77. Lorenzo-Betancor O, Mehta S, Ramchandra J, Mumuney S, Schumacher-Schuh AF, Cornejo-Olivas M, Sarapura-Castro EH, Torres L, Inca-Martinez MA, Mazzetti P, Cosentino C, Micheli F, Tumas V, Dieguez E, Raggio V, Borges V, Ferraz HB, Chana-Cuevas P, Jimenez-Del-Rio M, Velez-Pardo C, Moreno S, Lopera F, Orozco-Velez JL, Muñoz-Ospina B, Rieder CRM, Medina-Escobar A, Yearout D, Zabetian CP, Mata IF; Latin American Research Consortium on the Genetics of PD (LARGE-PD). Parkinson's Disease Gene Screening in Familial Cases from Central and South America. *Mov Disord.* 2024 Jul 25. doi: 10.1002/mds.29931. Online ahead of print. PMID: 39051491
78. Wandell CJ, Torres K. Exploring the utility of process scores in elucidating the role of cognitive and affective factors that influence verbal fluency performance in Parkinson's disease. *Appl Neuropsychol Adult.* 2024 Jun 3:1-12. doi: 10.1080/23279095.2024.2359446. Online ahead of print. PMID: 38828539
79. Torres K. Comparison of core and process scores on the California Verbal Learning Test-3 for Parkinson's disease and essential tremor patients. *J Clin Exp Neuropsychol.* 2023 Oct;45(8):798-812. doi: 10.1080/13803395.2023.2241653. Epub 2023 Jul 28. PMID: 37505187
80. Torres K, Singleton M. Analyses of correct responses and errors on measures of verbal fluency among Parkinson's disease and essential tremor patients. *Clin Neuropsychol.* 2023 Oct;37(7):1479-1497. doi: 10.1080/13854046.2022.2157885. Epub 2022 Dec 22. PMID: 36550679
81. Leal TP, Rao SC, French-Kwawu JN, Gouveia MH, Borda V, Bandres-Ciga S, Inca-Martinez M, Mason EA, Horimoto ARVR, Loesch DP, Sarihan EI, Cornejo-Olivas MR, Torres LE, Mazzetti-Soler PE, Cosentino C, Sarapura-Castro EH, Rivera-Valdivia A, Medina AC, Dieguez EM, Raggio VE, Lescano A, Tumas V, Borges V, Ferraz HB, Rieder CR, Schumacher Schuh A, Santos-Lobato BL, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Moreno S, Chana-Cuevas P, Fernandez W, Arboleda G, Arboleda H, Arboleda Bustos CE, Yearout D, Barbosa MT, Cardoso FEC, Caramelli P, Cunningham MCQ, Maia DP, Lima-Costa MF, Tarazona-Santos E, Zabetian CP; International Parkinson Disease Genomics Consortium (IPDGC); Thornton TA, O'Connor TD, Mata IF; Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD). X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease. *Mov Disord.* 2023 Sep;38(9):1625-1635. doi: 10.1002/mds.29508. Epub 2023 Jul 20. PMID: 37469269

82. Gasca-Salas C, Duff-Canning S, McArthur E, Armstrong MJ, Fox S, Meaney CA, Tang-Wai DF, Gill D, Eslinger PJ, Zadikoff C, Marshall FJ, Mapstone M, Chou KL, Persad C, Litvan I, Mast BT, Gerstenecker AT, Weintraub S, Marras C. Predictors of Cognitive Change in Parkinson Disease: A 2-year Follow-up Study. *Alzheimer Dis Assoc Disord*. 2023 Oct-Dec 01;37(4):335-342. doi: 10.1097/WAD.0000000000000576. Epub 2023 Aug 22. PMID: 37615480
83. Fernandez HH, Weintraub D, Macklin E, Litvan I, Schwarzschild MA, Eberling J, Videnovic A, Kenney CJ; Parkinson Study Group SYNAPSE Investigators. Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT₆/5-HT_{2A} antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial. *Parkinsonism Relat Disord*. 2023 Sep;114:105511. doi: 10.1016/j.parkreldis.2023.105511. Epub 2023 Jul 13. PMID: 37532622
84. Petkus AJ, Donahue E, Jakowec MW, Bayram E, Van Horn JD, Litvan I, Petzinger GM, Schiehser DM. Data-driven sequence of cognitive decline in people with Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2024 May 30;jnnp-2023-333270. doi: 10.1136/jnnp-2023-333270. Epub ahead of print. PMID: 38816189
85. Split M, Pluim McDowell C, Lopez FV, Almklov E, Filoteo JV, Lessig S, Litvan I, Schiehser DM. The relationship between objective and subjective executive function in Parkinson's disease. *J Clin Exp Neuropsychol*. 2024 Apr;46(3):207-217. doi: 10.1080/13803395.2024.2340812. Epub 2024 May 9. PMID: 38721997
86. Bayram E, Reho P, Litvan I; International LBD Genomics Consortium; Ding J, Gibbs JR, Dalgard CL, Traynor BJ, Scholz SW, Chia R. Genetic analysis of the X chromosome in people with Lewy body dementia nominates new risk loci. *NPJ Parkinsons Dis*. 2024 Feb 20;10(1):39. doi: 10.1038/s41531-024-00649-7. PMID: 38378815; PMCID: PMC10879525
87. Foreman RP, Donahue EK, Duran JJ, Schiehser DM, Petkus A, O'Neill J, Holschneider DP, Choupan J, Van Horn JD, Bayram E, Litvan I, Jakowec MW, Petzinger GM. High baseline perivascular space volume in basal ganglia is associated with attention and executive function decline in Parkinson's disease. *Brain Behav*. 2024 Jul;14(7):e3607. doi: 10.1002/brb3.3607. PMID: 39010690; PMCID: PMC11250171
88. Bayram E, Coughlin DG, Rajmohan R, Litvan I. Sex differences for clinical correlates of substantia nigra neuron loss in people with Lewy body pathology. *Biol Sex Differ*. 2024 Jan 19;15(1):8. doi: 10.1186/s13293-024-00583-6. PMID: 38243325; PMCID: PMC10797801
89. Cardoso F, Goetz CG, Mestre TA, Sampaio C, Adler CH, Berg D, Bloem BR, Burn DJ, Fitts MS, Gasser T, Klein C, de Tijssen MAJ, Lang AE, Lim SY, Litvan I, Meissner WG, Mollenhauer B, Okubadejo N, Okun MS, Postuma RB, Svenningsson P, Tan LCS, Tsunemi T, Wahlstrom-Helgren S, Gershanik OS, Fung VSC, Trenkwalder C. A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease. *Mov Disord*. 2024 Feb;39(2):259-266. doi: 10.1002/mds.29683. Epub 2023 Dec 13. PMID: 38093469
90. Jost ST, Aloui S, Evans J, Ashkan K, Sauerbier A, Rizos A, Petry-Schmelzer JN, Gronostay A, Fink GR, Visser-Vandewalle V, Antonini A, Silverdale M, Timmermann L, Martinez-Martin P, Chaudhuri KR, Dafsari HS; International Parkinson and Movement Disorders Society Non-

Motor Parkinson's Disease Study Group and EUROPAR. Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial. *JAMA Netw Open*. 2024 Jan 2;7(1):e2352177. doi: 10.1001/jamanetworkopen.2023.52177. PMID: 38236600; PMCID: PMC10797423

91. Williams GP, Michaelis T, Lima-Junior JR, Frazier A, Tran NK, Phillips EJ, Mallal SA, Litvan I, Goldman JG, Alcalay RN, Sidney J, Sulzer D, Sette A, Lindestam Arlehamn CS. PINK1 is a target of T cell responses in Parkinson's disease. *bioRxiv [Preprint]*. 2024 Feb 12:2024.02.09.579465. doi: 10.1101/2024.02.09.579465. PMID: 38405939; PMCID: PMC10888789
92. Sauerbier A, Herberg J, Stopic V, Loehrer PA, Ashkan K, Rizos A, Jost ST, Petry-Schmelzer JN, Gronostay A, Schneider C, Visser-Vandewalle V, Evans J, Nimsky C, Fink GR, Antonini A, Martinez-Martin P, Silverdale M, Weintraub D, Schrag A, Ray Chaudhuri K, Timmermann L, Dafsari HS; EUROPAR, the German Parkinson Society Non-motor Symptoms Study Group, and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group. Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson's disease. *NPJ Parkinsons Dis*. 2024 Jun 8;10(1):114. doi: 10.1038/s41531-024-00701-6. PMID: 38851717; PMCID: PMC11162430
93. Donahue EK, Foreman RP, Duran JJ, Jakowec MW, O'Neill J, Petkus AJ, Holschneider DP, Choupan J, Van Horn JD, Venkadesh S, Bayram E, Litvan I, Schiehser DM, Petzinger GM. Increased perivascular space volume in white matter and basal ganglia is associated with cognition in Parkinson's Disease. *Brain Imaging Behav*. 2024 Feb;18(1):57-65. doi: 10.1007/s11682-023-00811-4. Epub 2023 Oct 19. PMID: 37855955; PMCID: PMC10844402
94. Bayram E, Liu H, Luo S, Di Luca DG, Skipworth M, Damron Solomon L, Dahodwala N, Litvan I. Ethnoracial differences for caregiving burden in Parkinson's disease. *Parkinsonism Relat Disord*. 2024 Jan;118:105927. doi: 10.1016/j.parkreldis.2023.105927. Epub 2023 Nov 7. PMID: 37952272; PMCID: PMC10911683
95. Mahato K, Moon JM, Moonla C, Longardner K, Ghodsi H, Litvan I, Wang J. Biosensor Strip for Rapid On-site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease. *Angew Chem Int Ed Engl*. 2024 Jul 1;63(27):e202403583. doi: 10.1002/anie.202403583. Epub 2024 May 28. PMID: 38682251.
96. Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Foroud T, Hall A, Marder KS, Mata IF, Mencacci NE, Nance MA, Schwarzschild MA, Simuni T, Bressman S, Wills AM, Fernandez HH, Litvan I, Lyons KE, Shill HA, Singer C, Tropea TF, Arroyave NV, Carbonell J, Vicioso RC, Katus L, Quinn JF, Hodges PD, Meng Y, Strom SP, Blauwendraat C, Lohmann K, Casaceli C, Rao SC, Galvelis KG, Naito A, Beck JC, Alcalay RN. Parkinson's disease variant detection and disclosure: PD GENERation, a North American study. *Brain*. 2024 Jul 30:awae142. doi: 10.1093/brain/awae142. Epub ahead of print. PMID: 39074992
97. Pelak VS. Hallucinations, Visual and Auditory. Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier; 2024. <https://doi.org/10.1016/B978-0-323-95702-1.00092-0>

98. Kawakami R, Wright KD, Scharre DW, Ning X. Detection of Cognitive Impairment From eSAGE Metadata Using Machine Learning. *Alzheimer Dis Assoc Disord*. 2024 Jan-Mar 01;38(1):22-27. doi: 10.1097/WAD.0000000000000593. Epub 2023 Dec 13. PMID: 38109352. Study specifically including DLB subjects
99. Scharre DW, Vrettos NE, Nagaraja HN, Wexler RK, Clark AD, Nguyen CM. Self-administered gerocognitive examination (SAGE) aids early detection of cognitive impairment at primary care provider visits. *Front Med (Lausanne)*. 2024 Jun 13;11:1353104. doi: 10.3389/fmed.2024.1353104. PMID: 38938387; PMCID: PMC11208700. Study specifically including DLB subjects
100. Beach TG, Adler CH, Shill HA, Serrano G, Zhang N, Driver-Dunckley E, Mehta SH. Accuracy of the Clinical Diagnosis of Early Parkinson's Disease. *Movement Disorders* 2023; 38: 1573-74. DOI: 10.1002/mds.29556. PMID: 37565398
101. Beach TG, Adler CH, Shill HA, Serrano GE, Zhang N. α -synuclein seed amplification in Parkinson's disease. *Lancet Neurol*. 2023;22:985. doi: 10.1016/S1474-4422(23)00373-3. PMID: 37863604
102. Olson MC, Shill H, Ponce F, Aslam S. Deep brain stimulation in PD: risk of complications, morbidity and hospitalizations: a systematic review. *Frontiers Aging Neurosci*, 2023 Nov 17:15:1258190. doi:10.3389/fnagi.2023.1258190. PMID: 38046469
103. Adler CH, Serrano G, Shill H, Driver-Dunckley E, Mehta S, Zhang N, Glass M, Sue L, Introcia A, Beach TG. Symmetry of synuclein density in autopsied Parkinson's disease submandibular glands. *Neuroscience Letters* 2024 March 10. <https://doi.org/10.1016/j.neulet.2024.137702>. PMID: 38395191
104. Tremblay C, PhD, Aslam S, Walker JE, Lorenzini I, Intorcica AJ, Arce RA, Choudhury P, Adler CH, Shill HA, Driver-Dunckley E, Mehta S, Belden CM, Atria, Beach TG, Serrano GE. RNA sequencing of olfactory bulb in aging and Parkinson's disease reveals gene alterations associated with olfactory dysfunction. *Neurobiology of disease*, 2024 Jun 15;196:106514. doi: 10.1016/j.nbd.2024.106514. Epub 2024 Apr 24. PMID: 38663633
105. Griffith S, Conrow K, Go M, McEntee M, Daniulaityte R, Nadesan M, Swinburne M, Shill H, Leung M. Cannabis use in Parkinson's disease. Patient access to medical cannabis and physician perspective on product safety. *Neurotoxicology*, <https://doi.org/10.1016/j.neuro.2024.05.008>. PMID: 38834158
106. Agin-Liebes J, Hickman RA, Vonsattel JP, Faust PL, Flowers X, Utkina Sosunova I, et al. Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations. *Mov Disord*. 2023
107. Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Beck JC, Naito A, et al. Providing Genetic Testing and Genetic Counseling for Parkinson's Disease to the Community. *Genet Med*. 2023:100907
108. Pal G, Cook L, Schulze J, Verbrugge J, Alcalay RN, Merello M, et al. Genetic Testing in Parkinson's Disease. *Mov Disord*. 2023

109. Saunders-Pullman R, Raymond D, Ortega RA, Shalash A, Gatto E, Salari M, et al. International Genetic Testing and Counseling Practices for Parkinson's Disease. *Mov Disord.* 2023
110. Huddleston DE, Chen X, Hwang KS, Langley J, Tripathi R, Tucker K, McKay JL, Hu XP, Factor XA. Neuromelanin-sensitive MRI correlates of cognition, motor function, and aging in Parkinson's disease with freezing of gait. *Frontiers Dementia.* (2023) Aug 11;2. doi: 10.3389/frdem.2023.1215505
111. Phongpreecha T, Godrich D, Berson E, Espinosa C, Kim Y, Cholerton B, Chang AL, Mataraso S, Bukhari SA, Perna A, Yakabi K, Montine KS, Poston KL, Mormino E, White L, Beecham G, Aghaeepour N, Montine TJ. Quantitative estimate of cognitive resilience and its medical and genetic associations. *Alzheimers Res Ther.* 2023 Nov 6;15(1):192
112. Armstrong MJ, Bedenfield N, Rosselli M, Curiel-Cid RE, Kitaigorodsky M, Galvin JE, Lachner C, Grant Smith A, de los Ángeles Ortega M, Mohiuddin Y, Shatzer J, Marasco D, Willis D, Bylund CL. Best practices for communicating a diagnosis of dementia: results of a multi-stakeholder modified Delphi consensus process. *Neurology Clinical Practice* 2024 Feb;14(1):e200223. doi: 10.1212/CPJ.0000000000200223